News about "Levi Garraway"

US FDA Approves Roche's Enspryng for Thyroid Eye Disease

The US FDA has approved Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED).

Levi Garraway | 17/10/2026 | By News Bureau

Roche's Tecentriq Wins US FDA Approval for Stage 3 Colon Cancer

The US FDA has approved Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage 3 colon cancer.

Levi Garraway | 13/10/2026 | By News Bureau

Roche's Sefaxersen Cuts Proteinuria in IgA Nephropathy

Roche’s sefaxersen significantly reduces proteinuria in IgA nephropathy, with Phase III IMAgINATION data showing meaningful results versus placebo.

Levi Garraway | 24/09/2026 | By News Bureau

Roche Reports Positive Phase 2 Results for Enicepatide

Roche has announced positive phase 2 results for dual GLP-1/GIP receptor agonist enicepatide in people living with Type 2 Diabetes and overweight or obesity.

Levi Garraway | 23/09/2026 | By News Bureau |  119

US FDA Grants Priority Review to Genentech?s Enspryng for MOGAD

The US Food and Drug Administration (FDA) has granted priority review to Genentech’s Enspryng for MOGAD after phase 3 METEOROID data showed a 68 percent reduction in relapse risk.

Levi Garraway | 11/09/2026 | By News Bureau

CHMP Recommends EU Approval of Roche's Susvimo

The Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval of Roche's Susvimo, the first continuous delivery treatment offering an alternative to regular eye injections for wet Age-related Macular Degeneration (AMD).

Levi Garraway | 25/07/2026 | By News Bureau |  139

Roche's Gazyva Receives US FDA Priority Review for Membranous Nephropathy

The US Food and Drug Administration (FDA) has granted Priority Review to Roche's Gazyva for primary membranous nephropathy, supported by phase 3 MAJESTY trial results showing superior complete remission versus tacrolimus.

Levi Garraway | 17/07/2026 | By News Bureau |  163

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial

Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.

Levi Garraway | 04/07/2026 | By News Bureau |  310

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).

Levi Garraway | 02/07/2026 | By News Bureau |  187

Roche's Enspryng Receives FDA Priority Review for Thyroid Eye Disease

Roche's Enspryng has received FDA Priority Review for thyroid eye disease after Phase 3 studies demonstrated clinically meaningful improvements in eye bulging, disease activity and double vision, with a regulatory decision expected by October 2026.

Levi Garraway | 01/07/2026 | By News Bureau |  158